You are here

Microfluidic Processing of Leukocytes for Molecular Diagnostic Testing

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R42CA174121-02
Agency Tracking Number: R42CA174121
Amount: $1,434,795.00
Phase: Phase II
Program: STTR
Solicitation Topic Code: 102
Solicitation Number: PA14-072
Solicitation Year: 2014
Award Year: 2015
Award Start Date (Proposal Award Date): 2015-05-18
Award End Date (Contract End Date): 2018-04-30
Small Business Information
Richmond, VA 23219-1551
United States
DUNS: 832526581
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (609) 258-5610
Business Contact
Phone: (609) 258-5610
Research Institution
United States

 Domestic Nonprofit Research Organization

DESCRIPTION provided by applicant The goal of this Phase II project is to optimize and validate a microfluidic chip based process that automates and shortens the labeling washing and collecting of human blood leukocytes WBCs for flow cytometric analysis of clinically important cell surface and intracellular markers Multi parameter flow cytometry is an increasingly powerful and widely used technology in research and in clinical diagnostic testing for cancer and many other diseases There is a critical need for new methods to improve the efficiency of sample preparation which is laborious and variable and typically requires many cycles of washing collecting cells by centrifugation GPB LLC is developing a novel microfluidic Deterministic Lateral Displacement DLD chip processing technology that can harvest cells from a flow of fluid on the basis of size A mixture of fluid and particles flows through an array f microposts that are tilted at a small angle from the direction of the fluid flow Cells within the target size range are deflected off the microposts in a process that is rapid yet gentle The novel
disposable DLD chips will allow automation and potentially combination of the processes of labeling fixing and washing cells from very small samples of whole blood The Phase I STTR project a collaboration among GPB Princeton University and the University of Maryland UM successfully demonstrated proof of principle by showing that prototype DLD chips can harvest monoclonal antibody Mab labeled WBCs from human whole blood with high cell recovery and viability while removing the large excess of red blood cells RBCs and unbound Mab and without skewing the distribution of WBC subsets The objective of this Phase II project is to optimize a suite of DLD chips and processes as prototype commercial products Aim is to design and optimize DLD chip based systems for washing and concentrating human blood WBCs Aim is to design and validate DLD chip based systems for surface labeling on chip fixation permeabilization or intracellular labeling of WBCs combined with on chip washing Aim is to develop a DLD chip based system to fix permeabilize intracellularly label wash and concentrate WBCs on a single chip Aim is to produce prototype application specific chips and an automated platform product to control WBC processing via a user interface Cell labeling will be tested with panels of Mab reagents and cocktails that are commonly used for cell surface labeling and for intracellular labeling in clinical diagnostic prognostic and research testing Outcomes will be measured by flow cytometry in several laboratories at UM GBP and several collaborating large diagnostic companies Some of these companies have expressed interest in helping to commercialize chip and processing system products PUBLIC HEALTH RELEVANCE Flow cytometry for single cell analysis is a widely used analytical method for research clinical diagnosis and treatment monitor but the multi step cell staining protocols are manual tedious and fraught with variability The novel GPB novel microfluidic technology platform will simplify automate and reduce the cost of the cell processing steps and decrease sample variability Successful completion of this Phase II project will result in a suite of products that will start with whole blood and generate purified WBC samples that are ready for flow cytometric analysis Moreover these products also will facilitate sample preparation for other powerful new technologies such as mass cytometry rare cell isolation single cell genomics proteomics metabolomics and a wide range of new techniques under development

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government